 **Raymed Labs Ltd.**

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :  
GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com  
Tel. 0132-3242000

30.05.2016

The Manager-Listing  
The Department of Corporate Services  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai- 400001

**Sub: Rectified Statement of Assets & Liabilities**

**BSE Company Code: 531207**

Dear Sir/Madam,


Please find attached the rectified Statement of Assets & Liabilities along with Annual Audited Financial Results for the quarter ended 31<sup>st</sup> March, 2016.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,

For Raymed Labs Limited

  
Ajai Goyal

Director


(Whole Time Director)

DIN: 02636418

CC: Ahmedabad Stock Exchange Limited

**Audited Financial Results for the Quarter/Year Ended on March 31, 2016**

PART I		Rs. in Lacs				
Particulars	3 Months Ended 31-03-2016	Preceding 3 Months Ended 31-12-2015	Corresponding 3 Months in the Previous Year Ended 31-03-2015	Year to Date Figures for Current Period Ended 31-03-2016	Previous Year Ended 31-03-2015	
	Audited	Unaudited	Audited	Audited	Audited	
<b>1 Income from Operations</b>						
(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	
(b) Other Operating Income	-	-	-	-	-	
<b>Total Income from Operations (net)</b>	-	-	-	-	-	
<b>2 Expenses</b>						
(a) Cost of materials consumed	-	-	-	-	-	
(b) Purchase of stock-in-trade	-	-	-	-	-	
Changes in inventories of finished goods,						
(c) work-in-progress and stock-in-trade	-	-	-	-	-	
(d) Employee expenses & benefits	0.23	0.23	0.15	0.90	1.00	
(e) Depreciation and amortisation expense	0.89	-	-	0.89	-	
(f) Other expenses	0.26	0.14	0.43	1.63	2.99	
<b>Total Expenses</b>	<b>1.38</b>	<b>0.37</b>	<b>0.58</b>	<b>3.42</b>	<b>3.99</b>	
<b>3 Profit/(Loss) from Operations before other Income, Finance costs and Exceptional Items (1-2)</b>	-1.38	-0.37	-0.58	-3.42	-3.99	
4 Other Income	0.30	0.54	0.54	1.92	2.16	
<b>5 Profit/Loss from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>-1.08</b>	<b>0.17</b>	<b>-0.04</b>	<b>-1.50</b>	<b>-1.83</b>	
6 Finance Costs	-	-	0.00	-	0.00	
<b>7 Profit/Loss from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>-1.08</b>	<b>0.17</b>	<b>-0.04</b>	<b>-1.50</b>	<b>-1.83</b>	
8 Exceptional Items	2.25	-	-	2.25	-	
<b>9 Profit/Loss from Ordinary Activities before tax (7-8)</b>	<b>-3.32</b>	<b>0.17</b>	<b>-0.04</b>	<b>-3.75</b>	<b>-1.83</b>	
10 Tax Expense	-	-	-	-	-	
<b>11 Net Profit/ Loss from Ordinary Activities after Tax (9-10)</b>	<b>-3.32</b>	<b>0.17</b>	<b>-0.04</b>	<b>-3.75</b>	<b>-1.83</b>	
12 Extraordinary Item (net of tax expense)	-	-	-	-	-	
<b>13 Net Profit/ Loss for the period (11-12)</b>	<b>-3.32</b>	<b>0.17</b>	<b>-0.04</b>	<b>-3.75</b>	<b>-1.83</b>	
17 Paid up Equity Share Capital (Face Value Rs.10/- per share)	427.35	427.35	427.35	427.35	427.35	
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	
<b>19 i Earning Per Share (before extraordinary items)</b>	<b>-0.078</b>	<b>0.004</b>	<b>-0.00</b>	<b>-0.088</b>	<b>-0.04</b>	
<b>19 ii Earning Per Share (after extraordinary items)</b>	<b>-0.078</b>	<b>0.004</b>	<b>-0.00</b>	<b>-0.088</b>	<b>-0.04</b>	

  
 Director

PART II						
Particulars	3 Months Ended 31-03-2016	Preceding 3 Months Ended 31-12-2015	Corresponding 3 Months in the Previous Year Ended 31-03-2015	Year to Date Figures for Current Period Ended 31-03-2016	Previous Year Ended 31-03-2015	
<b>A PARTICULARS OF SHAREHOLDING</b>						
1 Public Shareholding						
- Number of shares	3,061,450	3,061,450	3,061,450	3,061,450	3,061,450	
- Percentage of shareholding	71.64%	71.64%	71.64%	71.64%	71.64%	
2 Promoters and promoter group Shareholding						
a) Pledged/Encumbered						
- Number of shares	Nil	Nil	Nil	Nil	Nil	
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	
b) Non-encumbered						
- Number of Shares	1,212,050	1,212,050	1,212,050	1,212,050	1,212,050	
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	
- Percentage of shares (as a % of the total share capital of the company)	28.36%	28.36%	28.36%	28.36%	28.36%	

Notes:

- The Audited financial statements for the quarter ended on March 31, 2016 as reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 28, 2016. The information presented above is extracted from the financial statement.
- The figures of the last quarter of current and corresponding previous year are the balancing figures between the audited figures of the full financial year and published year to date figures upto the third quarter of the financial year.
- EPS has been calculated in accordance with AS-20 issued by ICAI.
- The Business of the Company falls under a single segment for the purpose of Accounting Standard As-17, issued by The Institute of Chartered Accountants of India.
- Previous period/year figures have been regrouped/rearranged, wherever found necessary.
- No investor complaints were pending in the beginning and end of the quarter ended March 2016.

For Raymed Labs Limited

For RAYMED LABS LTD  
 Ajay Goyal  
 Place: NOIDA  
 Date: 28-05-2016  
 Director



**Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015**

To the Board of Directors

**RAYMED LABS LIMITED**

We have audited the quarterly financial results of **RAYMED LABS LIMITED** for the quarter ended March 31, 2016 and the year to date results for the period April 1, 2015 to March 31, 2016 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements), Regulations 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards for Interim Financial Reporting (AS) 25 prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly and year to date financial results:

- i) has been presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements), Regulations 2015 in this regard; and
- ii) give a true and fair view of the net profit/loss and other financial information for the quarter ended March 31, 2016 as well as the year to date results for the period from April 1, 2015 to March 31, 2016.

For **A. KAY. MEHRA & CO.**  
Chartered Accountants  
(Registration No. 050004C)



**DEEPAK SUNEJA**  
Partner  
Membership No. 501957


Place: Delhi.  
Date: 28.05.2016

ANNEXURE X

Form A (for audit report with unmodified opinion) or Form B (for audit report with modified opinion)  
along-with Financial Results

FORM A (for audit report with unmodified opinion)

1.	Name of the company	RAYMED LABS LIMITED
2.	Annual financial statements for the year ended	31 <sup>st</sup> March, 2016
3.	Type of Audit observation	Un Modified
4.	Frequency of observation	Repetitive
5.	To be signed by- <ul style="list-style-type: none"> <li>• CEO/Managing Director</li> <li>• CFO</li> <li>• Auditor of the company</li> <li>• Audit Committee Chairman</li> </ul>	<p>Stamp: FOR RAYMED LABS LIMITED</p> <p>AJAI GOYAL <i>Ajai Goyal</i></p> <p>Nisha <i>Nisha</i></p> <p>DEEPAK SUNEJA <i>Deepak Suneja</i></p>



*Ajai Goyal*

# RAYMED LABS LIMITED

Registered Office: Greenland Industrial Complex, Dehradun Road, Saharanpur, Uttar Pradesh Ph: 0132-3242000  
Email id: raymedlabs@rediffmail.com, CIN- L24111UP1992PLC014240

Statement of Assets and Liabilities		Rs. in Lakhs	
	Particulars	As at Current year ended 31-03-2016	As at previous year ended 31-03-2015
<b>A</b>	<b>EQUITY AND LIABILITES</b>		
<b>1</b>	<b>Shareholders Funds:</b>		
	(a) Share Capital	427.35	427.35
	(b) Reserves and Surplus	-604.17	-600.42
	(c) Money Received against share warrants	-	-
	<b>Sub-total -Shareholder's funds</b>	<b>-176.82</b>	<b>-173.07</b>
	<b>2</b> Share Application Money pending allotment	-	-
	<b>3</b> Minority interest *	-	-
	<b>4 Non -Current liabilites</b>		
	(a)Long -Term borrowings	-	-
	(b) Deffered Tax Liabilites (net)	-	-
	(c) Other long term borrowings	-	-
	(d) long term proivisons	-	-
	<b>Sub-total -Non Current Liabilites</b>	<b>0.00</b>	<b>0.00</b>
	<b>5 Current Liabilities</b>		
	(a) Short Term Borrowings	198.6	199.60
	(b) Trade Payables	-	-
	(c) other current liabilities	6.15	3.75
	(d) Short term Provisions	-	-
	<b>Sub-total -Current liabilities</b>	<b>204.75</b>	<b>203.35</b>
	<b>TOTAL -EQUITY AND LIABILITES</b>	<b>27.93</b>	<b>30.28</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non current assets</b>		
	(a) Fixed Assets(Net)	19.31	20.20
	(b) Goodwill on consolidation	-	-
	(c) Non - Current investment	-	-
	(d) Deffered Tax assets (net)	-	-
	(e) Long terms loans and advances	-	-
	Other non -current assets (profit & loss)	-	-
	<b>Sub-total --non -current assets</b>	<b>19.31</b>	<b>20.20</b>

For RAYMED LABS LTD  
*Ajay Goyal*  
Director

<b>2</b>	<b>Current Assets</b>		
	(a) Current investment	-	-
	(b) Inventories	-	-
	(c) Trade receivable	2.49	2.49
	(d) cash and cash equivalent	0.03	0.49
	(e) Short- term loans and advances	6.1	7.10
	(f) Other current assets	-	-
	<b>Sub-total -current assets</b>	<b>8.62</b>	<b>10.08</b>
	<b>TOTAL- ASSETS</b>	<b>27.93</b>	<b>30.28</b>

Place: I Noida  
Dated : 28.05.2016

For Raymed Labs Limited

For RAYMED LABS LTD  
*Ajai Goyal*  
Director

Ajai Goyal  
Director  
DIN: 02636418